VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, August 16th.

VolitionRx Stock Performance

VolitionRx stock opened at $0.81 on Wednesday. The firm has a 50 day moving average price of $0.68 and a 200 day moving average price of $0.68. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.23. The company has a market capitalization of $75.16 million, a PE ratio of -2.25 and a beta of 1.10.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.